Japan's Fuji Pharma penetrates Thailand

 

 

“This decision is in line with our strategy for sustainable profitable growth, where our focus is on our core competency as a provider of Market Expansion Services, from sourcing, marketing, sales, distribution to after-sales services. The OLIC contract manufacturing facility is a heritage, non-core activity of DKSH, and is more optimally positioned in the hands of Fuji which has significant expertise in this sector. DKSH will be investing the proceeds into our core business to create higher value for shareholders,” said Dr. Joerg Wolle, president & CEO of DKSH Group.

The transaction was unveiled on August 3.

OLIC was founded in 1961. It provides contract manufacturing services for pharmaceutical, healthcare, confectionaries, and supplementary industries. The company employs over 850 people, manufacturing over 550 products for more than 35 multinational corporations. OLIC’s annual sales reached around Bt1 billion in 2011.

Hirofumi Imai, president & CEO of Fuji Pharma comments, said that the acquisition is an important step for Fuji Pharma's expansion outside Japan. 

"Through the acquisition of OLIC, we are gaining a bestin-class contract manufacturing business that is highly reputable, profitable, and well-run by highly trained and competent staff according to international Good Manufacturing Practice standards. OLIC fits perfectly with our existing operations and business in Japan and in Asia, and we are committed to investing and growing OLIC even more, and further enhancing its already well-established reputation and performance," Imai said.

Charles Toomey, global Head Business Unit Healthcare, DKSH, noted that Fuji’s decision to expand its operations into Thailand is proof of the increasing trend of Asian companies investing and growing in their own region, thereby driving inner-Asian growth.